Metastatic Triple-Negative Breast Cancer Ongoing Trials

A discussion on various ongoing clinical trials regarding the management of metastatic triple-negative breast cancer.

Data from the following clinical trials are discussed:

• KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (Cortes, ASCO 2020 Abstract 1000)

• TBCRC 048: A phase II study of olaparib in metastatic breast cancer patients with germline or somatic mutations in DNA damage response pathway genes (Olaparib Expanded). (Tung, ASCO 2020 Abstract 1002)

• Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer and/or germline BRCA-associated breast cancer (SWOG S1416). (Sharma, ASCO 2020 Abstract 1001)